Pirtobrutinib; A next generation; Highly selective; Non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Weirda, W. G.; Cheah, C. Y.; Roeker, L. E.; Patel, M. R.; Fakhri, B.; Barve, M. A.; Tam, C.; Lewis, D.; Gerson, J. N.; Alencar, A. J.; Ghia, P.; Schuster, S. J.; Davids, M. S.; Brown, J. R.; Jurczak, W.; Mato, A. R. |
| Abstract Title: | Pirtobrutinib; A next generation; Highly selective; Non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study |
| Meeting Title: | 2022 Deutscher Krebskongress. Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 45 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2022 Nov 13-16 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2022-11-01 |
| Start Page: | 167 |
| End Page: | 168 |
| Language: | English |
| ACCESSION: | WOS:000883051700391 |
| PROVIDER: | wos |
| DOI: | 10.1159/000521004 |
| Notes: | Meeting Abstract: 349 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
